Item Type | Name |
Academic Article
|
Severe periorbital edema secondary to STI571 (Gleevec).
|
Academic Article
|
Congestive heart failure is a rare event in patients receiving imatinib therapy.
|
Academic Article
|
Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia.
|
Academic Article
|
Kit inhibitor APcK110 induces apoptosis and inhibits proliferation of acute myeloid leukemia cells.
|
Academic Article
|
Development of Varicella-Zoster virus infection in patients with chronic myelogenous leukemia treated with imatinib mesylate.
|
Concept
|
Benzamides
|
Academic Article
|
Hematopoietic progenitor cell collection in patients with chronic myelogenous leukemia in complete cytogenetic remission after imatinib mesylate therapy.
|
Academic Article
|
Janus kinase 2: a critical target in chronic myelogenous leukemia.
|
Academic Article
|
AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has in vitro activity against imatinib-resistant chronic myeloid leukemia.
|
Academic Article
|
AMN107, a novel aminopyrimidine inhibitor of p190 Bcr-Abl activation and of in vitro proliferation of Philadelphia-positive acute lymphoblastic leukemia cells.
|
Academic Article
|
Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.
|
Academic Article
|
Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia.
|
Academic Article
|
A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome.
|
Academic Article
|
Imatinib mesylate resistance through BCR-ABL independence in chronic myelogenous leukemia.
|
Academic Article
|
Changes associated with the development of resistance to imatinib (STI571) in two leukemia cell lines expressing p210 Bcr/Abl protein.
|
Academic Article
|
Chronic myeloid leukemia in a patient with acquired immune deficiency syndrome: complete cytogenetic response with imatinib mesylate: report of a case and review of the literature.
|
Academic Article
|
Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate.
|
Academic Article
|
New targeted approaches in chronic myeloid leukemia.
|
Academic Article
|
New strategies in chronic myeloid leukemia.
|
Academic Article
|
Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate.
|
Academic Article
|
New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance.
|
Academic Article
|
Outcome of patients with Philadelphia chromosome-positive chronic myelogenous leukemia post-imatinib mesylate failure.
|
Academic Article
|
Phase 1 study of lonafarnib (SCH 66336) and imatinib mesylate in patients with chronic myeloid leukemia who have failed prior single-agent therapy with imatinib.
|
Academic Article
|
Phosphorylation levels of BCR-ABL, CrkL, AKT and STAT5 in imatinib-resistant chronic myeloid leukemia cells implicate alternative pathway usage as a survival strategy.
|
Academic Article
|
Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-alpha treatment.
|
Academic Article
|
Secondary myelodysplastic syndrome in a patient with Philadelphia-positive acute lymphoblastic leukemia after achieving a major molecular response with hyperCVAD plus imatinib mesylate.
|
Academic Article
|
Failure to achieve a major cytogenetic response by 12 months defines inadequate response in patients receiving nilotinib or dasatinib as second or subsequent line therapy for chronic myeloid leukemia.
|
Academic Article
|
Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia.
|
Academic Article
|
Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukemia in early chronic phase receiving high-dose or standard-dose imatinib therapy.
|
Academic Article
|
Predictors of primary imatinib resistance in chronic myelogenous leukemia are distinct from those in secondary imatinib resistance.
|
Academic Article
|
Significance of suboptimal response to imatinib, as defined by the European LeukemiaNet, in the long-term outcome of patients with early chronic myeloid leukemia in chronic phase.
|
Academic Article
|
Triptolide induces cell death independent of cellular responses to imatinib in blast crisis chronic myelogenous leukemia cells including quiescent CD34+ primitive progenitor cells.
|
Academic Article
|
Homoharringtonine, omacetaxine mepesuccinate, and chronic myeloid leukemia circa 2009.
|
Academic Article
|
Choosing the best treatment strategy for chronic myeloid leukemia patients resistant to imatinib: weighing the efficacy and safety of individual drugs with BCR-ABL mutations and patient history.
|
Academic Article
|
Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimization and selectivity study.
|
Academic Article
|
Survival outcomes for clonal evolution in chronic myeloid leukemia patients on second generation tyrosine kinase inhibitor therapy.
|
Academic Article
|
Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia.
|
Academic Article
|
Imatinib front-line therapy is safe and effective in patients with chronic myelogenous leukemia with pre-existing liver and/or renal dysfunction.
|
Academic Article
|
Nilotinib for the treatment of Philadelphia-chromosome-positive chronic myeloid leukemia.
|
Academic Article
|
Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib.
|
Academic Article
|
Activation of apoptosis signaling eliminates CD34+ progenitor cells in blast crisis CML independent of response to tyrosine kinase inhibitors.
|
Academic Article
|
Nilotinib in patients with Ph+ chronic myeloid leukemia in accelerated phase following imatinib resistance or intolerance: 24-month follow-up results.
|
Academic Article
|
Nilotinib-associated vascular events.
|
Academic Article
|
Chronic myeloid leukemia: 2012 update on diagnosis, monitoring, and management.
|
Academic Article
|
SL-401 and SL-501, targeted therapeutics directed at the interleukin-3 receptor, inhibit the growth of leukaemic cells and stem cells in advanced phase chronic myeloid leukaemia.
|
Academic Article
|
Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome.
|
Academic Article
|
Effects of signal transduction inhibitor 571 in acute myelogenous leukemia cells.
|
Academic Article
|
Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study.
|
Academic Article
|
Treatment of philadelphia chromosome-positive, accelerated-phase chronic myelogenous leukemia with imatinib mesylate.
|
Academic Article
|
In vitro effects of STI 571-containing drug combinations on the growth of Philadelphia-positive chronic myelogenous leukemia cells.
|
Academic Article
|
Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemia.
|
Academic Article
|
Quantitative polymerase chain reaction monitoring of BCR-ABL during therapy with imatinib mesylate (STI571; gleevec) in chronic-phase chronic myelogenous leukemia.
|
Academic Article
|
Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy.
|
Academic Article
|
Efficacy of imatinib mesylate in the treatment of idiopathic hypereosinophilic syndrome.
|
Academic Article
|
Prediction of initial cytogenetic response for subsequent major and complete cytogenetic response to imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia.
|
Academic Article
|
Philadelphia chromosome-positive leukemias: from basic mechanisms to molecular therapeutics.
|
Academic Article
|
Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders.
|
Academic Article
|
Anagrelide and imatinib mesylate combination therapy in patients with chronic myeloproliferative disorders.
|
Academic Article
|
The proteasome inhibitor PS-341 inhibits growth and induces apoptosis in Bcr/Abl-positive cell lines sensitive and resistant to imatinib mesylate.
|
Academic Article
|
Results of triple therapy with interferon-alpha, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in early chronic phase.
|
Academic Article
|
Analysis of the impact of imatinib mesylate therapy on the prognosis of patients with Philadelphia chromosome-positive chronic myelogenous leukemia treated with interferon-alpha regimens for early chronic phase.
|
Academic Article
|
Chromosomal abnormalities in Philadelphia chromosome-negative metaphases appearing during imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase.
|
Academic Article
|
Testing the prognostic model of Marin et al in an independent chronic myelogenous leukemia study group.
|
Academic Article
|
Troxacitabine and imatinib mesylate combination therapy of chronic myeloid leukaemia: preclinical evaluation.
|
Academic Article
|
High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia.
|
Academic Article
|
Beyond chronic myelogenous leukemia: potential role for imatinib in Philadelphia-negative myeloproliferative disorders.
|
Academic Article
|
Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia after failure of interferon-alpha.
|
Academic Article
|
Significance of myelofibrosis in early chronic-phase, chronic myelogenous leukemia on imatinib mesylate therapy.
|
Academic Article
|
Sudden blastic transformation in patients with chronic myeloid leukemia treated with imatinib mesylate.
|
Academic Article
|
Trends in the management of chronic myelogenous leukemia.
|
Academic Article
|
Targeting the kinase activity of the BCR-ABL fusion protein in patients with chronic myeloid leukemia.
|
Academic Article
|
Pregnancy among patients with chronic myeloid leukemia treated with imatinib.
|
Academic Article
|
Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet.
|
Academic Article
|
Effects of AMN107, a novel aminopyrimidine tyrosine kinase inhibitor, on human mast cells bearing wild-type or mutated codon 816 c-kit.
|
Academic Article
|
Myelodysplastic syndromes and acute leukemia developing after imatinib mesylate therapy for chronic myeloid leukemia.
|
Academic Article
|
Adaphostin has significant and selective activity against chronic and acute myeloid leukemia cells.
|
Academic Article
|
Dasatinib (BMS-354825) is active in Philadelphia chromosome-positive chronic myelogenous leukemia after imatinib and nilotinib (AMN107) therapy failure.
|
Academic Article
|
'Idiopathic' eosinophilia with an Occult T-cell clone: prevalence and clinical course.
|
Academic Article
|
The biology of chronic myelogenous leukemia: implications for imatinib therapy.
|
Academic Article
|
Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial.
|
Academic Article
|
A pilot study of imatinib, low-dose cytarabine and idarubicin for patients with chronic myeloid leukemia in myeloid blast phase.
|
Academic Article
|
Management of patients with newly diagnosed chronic myeloid leukemia: opportunities and challenges.
|
Academic Article
|
Emerging safety issues with imatinib and other Abl tyrosine kinase inhibitors.
|
Academic Article
|
The daunting task of modeling response to imatinib therapy in patients with chronic myelogenous leukemia.
|
Academic Article
|
Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance.
|
Academic Article
|
Current perspectives on the treatment of patients with chronic myeloid leukemia: an individualized approach to treatment.
|
Academic Article
|
Long-term experience with imatinib therapy in chronic phase chronic myelogenous leukemia--remarkable activity with room for improvement.
|
Academic Article
|
CXCR4 up-regulation by imatinib induces chronic myelogenous leukemia (CML) cell migration to bone marrow stroma and promotes survival of quiescent CML cells.
|
Academic Article
|
BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia: using guidelines to make rational treatment choices.
|
Academic Article
|
Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib.
|
Academic Article
|
Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy.
|
Academic Article
|
Sustained complete molecular response after imatinib discontinuation in a patient with chronic myeloid leukemia not previously exposed to interferon alpha.
|
Academic Article
|
Inhibition of mitochondrial metabolism by methyl-2-cyano-3,12-dioxooleana-1,9-diene-28-oate induces apoptotic or autophagic cell death in chronic myeloid leukemia cells.
|
Academic Article
|
Kinase domain point mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia emerge after therapy with BCR-ABL kinase inhibitors.
|
Academic Article
|
The effect of interleukin 11 on thrombocytopenia associated with tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia.
|
Academic Article
|
Circulating heat shock protein 70 and progression in patients with chronic myeloid leukemia.
|
Academic Article
|
Imatinib has limited therapeutic activity for hypereosinophilic syndrome patients with unknown or negative PDGFRalpha mutation status.
|
Academic Article
|
Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosis.
|
Academic Article
|
Second generation tyrosine kinase inhibitors for the treatment of chronic myelogenous leukemia. [An interview with Hagop Katarjian by H&O].
|
Academic Article
|
Jak2 inhibition deactivates Lyn kinase through the SET-PP2A-SHP1 pathway, causing apoptosis in drug-resistant cells from chronic myelogenous leukemia patients.
|
Academic Article
|
Treatment selection after imatinib resistance in chronic myeloid leukemia.
|
Academic Article
|
Dasatinib early intervention after cytogenetic or hematologic resistance to imatinib in patients with chronic myeloid leukemia.
|
Academic Article
|
Chronic myeloid leukemia (CML) with P190 BCR-ABL: analysis of characteristics, outcomes, and prognostic significance.
|
Academic Article
|
Synthetic tumor-specific breakpoint peptide vaccine in patients with chronic myeloid leukemia and minimal residual disease: a phase 2 trial.
|
Academic Article
|
Dasatinib-associated major molecular responses in patients with chronic myeloid leukemia in chronic phase following imatinib failure: response dynamics and predictive value.
|
Academic Article
|
Nonmyeloablative allogeneic stem cell transplantation for chronic myelogenous leukemia in the imatinib era.
|
Academic Article
|
Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet.
|
Academic Article
|
Optimizing therapy for patients with chronic myelogenous leukemia in chronic phase.
|
Academic Article
|
Current event-free survival after sequential tyrosine kinase inhibitor therapy for chronic myeloid leukemia.
|
Academic Article
|
Chronic myeloid leukemia and second-generation tyrosine kinase inhibitors: when, how, and which one?
|
Academic Article
|
Long-term prognostic impact of the use of erythropoietic-stimulating agents in patients with chronic myeloid leukemia in chronic phase treated with imatinib.
|
Academic Article
|
Front-line and salvage therapies with tyrosine kinase inhibitors and other treatments in chronic myeloid leukemia.
|
Academic Article
|
Impact of treatment end point definitions on perceived differences in long-term outcome with tyrosine kinase inhibitor therapy in chronic myeloid leukemia.
|
Academic Article
|
Aberrant DNA methylation is associated with disease progression, resistance to imatinib and shortened survival in chronic myelogenous leukemia.
|
Academic Article
|
Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial.
|
Academic Article
|
Chronic myeloid leukemia: mechanisms of resistance and treatment.
|
Academic Article
|
Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience.
|
Academic Article
|
Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure.
|
Academic Article
|
EUTOS score is not predictive for survival and outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors: a single institution experience.
|
Academic Article
|
Patient adherence to tyrosine kinase inhibitor therapy in chronic myeloid leukemia.
|
Academic Article
|
Philadelphia-positive acute lymphoblastic leukemia: current treatment options.
|
Academic Article
|
Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial.
|
Academic Article
|
Initial molecular response at 3 months may predict both response and event-free survival at 24 months in imatinib-resistant or -intolerant patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase treated with nilotinib.
|
Academic Article
|
Prediction of outcomes in patients with Ph+ chronic myeloid leukemia in chronic phase treated with nilotinib after imatinib resistance/intolerance.
|
Academic Article
|
Outcome after failure of second generation tyrosine kinase inhibitors treatment as first-line therapy for patients with chronic myeloid leukemia.
|
Academic Article
|
Similar outcome of patients with chronic myeloid leukemia treated with imatinib in or out of clinical trials.
|
Academic Article
|
Tyrosine kinase inhibition: a therapeutic target for the management of chronic-phase chronic myeloid leukemia.
|
Academic Article
|
Selective inhibition of cell proliferation and BCR-ABL phosphorylation in acute lymphoblastic leukemia cells expressing Mr 190,000 BCR-ABL protein by a tyrosine kinase inhibitor (CGP-57148).
|
Academic Article
|
Imatinib mesylate: clinical results in Philadelphia chromosome-positive leukemias.
|
Academic Article
|
Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase.
|
Academic Article
|
Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-alpha: follow-up results.
|
Academic Article
|
Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia.
|
Academic Article
|
Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.
|
Academic Article
|
Effects of age on prognosis with imatinib mesylate therapy for patients with Philadelphia chromosome-positive chronic myelogenous leukemia.
|
Academic Article
|
Prediction of initial cytogenetic response for subsequent major and complete cytogenetic response to imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia.
|
Academic Article
|
Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate.
|
Academic Article
|
Imatinib mesylate causes hypopigmentation in the skin.
|
Academic Article
|
Survival advantage with imatinib mesylate therapy in chronic-phase chronic myelogenous ;eukemia (CML-CP) after IFN-alpha failure and in late CML-CP, comparison with historical controls.
|
Academic Article
|
Periorbital oedema and epiphora as ocular side effects of imatinib mesylate (Gleevec).
|
Academic Article
|
Results of imatinib mesylate therapy in chronic myelogenous leukaemia with variant Philadelphia chromosome.
|
Academic Article
|
Investigational strategies in chronic myelogenous leukemia.
|
Academic Article
|
Imatinib mesylate therapy may overcome the poor prognostic significance of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia.
|
Academic Article
|
Chronic myeloid leukemia: current application of cytogenetics and molecular testing for diagnosis and treatment.
|
Academic Article
|
Survival benefit with imatinib mesylate therapy in patients with accelerated-phase chronic myelogenous leukemia--comparison with historic experience.
|
Academic Article
|
Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate.
|
Academic Article
|
The degree of bone marrow fibrosis in chronic myelogenous leukemia is not a prognostic factor with imatinib mesylate therapy.
|
Academic Article
|
Imatinib mesylate suppresses cytokine synthesis by activated CD4 T cells of patients with chronic myelogenous leukemia.
|
Academic Article
|
Pilot study of lonafarnib, a farnesyl transferase inhibitor, in patients with chronic myeloid leukemia in the chronic or accelerated phase that is resistant or refractory to imatinib therapy.
|
Academic Article
|
Staging of chronic myeloid leukemia in the imatinib era: an evaluation of the World Health Organization proposal.
|
Academic Article
|
Activity of AMN107, a novel aminopyrimidine tyrosine kinase inhibitor, against human FIP1L1-PDGFR-alpha-expressing cells.
|
Academic Article
|
Survival benefit with imatinib mesylate versus interferon-alpha-based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia.
|
Academic Article
|
Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.
|
Academic Article
|
Heterogeneity in detecting Abl kinase mutations and better sensitivity using circulating plasma RNA.
|
Academic Article
|
Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy.
|
Academic Article
|
In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate'.
|
Academic Article
|
Phase II study of low-dose decitabine in combination with imatinib mesylate in patients with accelerated or myeloid blastic phase of chronic myelogenous leukemia.
|
Academic Article
|
Results of a multicenter phase II trial for older patients with c-Kit-positive acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR-MDS) using low-dose Ara-C and Imatinib.
|
Academic Article
|
Introduction: chronic myelogenous leukemia (CML).
|
Academic Article
|
Important therapeutic targets in chronic myelogenous leukemia.
|
Academic Article
|
Diagnosis and management of chronic myeloid leukemia: a survey of American and European practice patterns.
|
Academic Article
|
Dasatinib for the treatment of Philadelphia chromosome-positive leukaemias.
|
Academic Article
|
The novel tyrosine kinase inhibitor EXEL-0862 induces apoptosis in human FIP1L1-PDGFR-alpha-expressing cells through caspase-3-mediated cleavage of Mcl-1.
|
Academic Article
|
Optimal first-line treatment of chronic myeloid leukemia. How to use imatinib and what role for newer drugs?
|
Academic Article
|
A critical appraisal of conventional and investigational drug therapy in patients with hypereosinophilic syndrome and clonal eosinophilia.
|
Academic Article
|
The prognosis for patients with chronic myeloid leukemia who have clonal cytogenetic abnormalities in philadelphia chromosome-negative cells.
|
Academic Article
|
Phase 1 study of tipifarnib in combination with imatinib for patients with chronic myelogenous leukemia in chronic phase after imatinib failure.
|
Academic Article
|
Tyrosine kinase inhibitors for chronic myelogenous leukemia.
|
Academic Article
|
Cytogenetic and molecular responses and outcome in chronic myelogenous leukemia: need for new response definitions?
|
Academic Article
|
An immunological method for the detection of BCR-ABL fusion protein and monitoring its activation.
|
Academic Article
|
The effects of imatinib on pregnancy outcome.
|
Academic Article
|
Molecular basis explanation for imatinib resistance of BCR-ABL due to T315I and P-loop mutations from molecular dynamics simulations.
|
Academic Article
|
Beyond dose escalation: clinical options for relapse or resistance in chronic myelogenous leukemia.
|
Academic Article
|
Activity of tyrosine kinase inhibitors against human NUP214-ABL1-positive T cell malignancies.
|
Academic Article
|
BCR-ABL alternative splicing as a common mechanism for imatinib resistance: evidence from molecular dynamics simulations.
|
Academic Article
|
Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy.
|
Academic Article
|
Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase.
|
Academic Article
|
Practical management of toxicities associated with tyrosine kinase inhibitors in chronic myeloid leukemia.
|
Academic Article
|
Complexity of BCR-ABL kinase domain mutations during the course of therapy with tyrosine kinase inhibitors in chronic myeloid leukemia.
|
Academic Article
|
Mechanisms of primary and secondary resistance to imatinib in chronic myeloid leukemia.
|
Academic Article
|
Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up.
|
Academic Article
|
Sustained durability of responses and improved progression-free and overall survival with imatinib treatment for accelerated phase and blast crisis chronic myeloid leukemia: long-term follow-up of the STI571 0102 and 0109 trials.
|
Academic Article
|
Tyrosine kinase inhibitor-induced platelet dysfunction in patients with chronic myeloid leukemia.
|
Academic Article
|
Imatinib mesylate therapy for polycythemia vera: final result of a phase II study initiated in 2001.
|
Academic Article
|
Imatinib and beyond--exploring the full potential of targeted therapy for CML.
|
Academic Article
|
Successful completion of pregnancy in a patient with chronic myeloid leukemia without active intervention: a case report and review of the literature.
|
Academic Article
|
High-dose imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: high rates of rapid cytogenetic and molecular responses.
|
Academic Article
|
The use of nilotinib or dasatinib after failure to 2 prior tyrosine kinase inhibitors: long-term follow-up.
|
Academic Article
|
Update: chronic myelogenous leukemia clinical practice guidelines.
|
Academic Article
|
Standard management of patients with chronic myeloid leukemia.
|
Academic Article
|
Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib.
|
Academic Article
|
Phase 1 study of INNO-406, a dual Abl/Lyn kinase inhibitor, in Philadelphia chromosome-positive leukemias after imatinib resistance or intolerance.
|
Academic Article
|
Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia.
|
Academic Article
|
Stem cell transplantation for patients with chronic myeloid leukemia resistant to tyrosine kinase inhibitors with BCR-ABL kinase domain mutation T315I.
|
Academic Article
|
Current and future management options for myelodysplastic syndromes.
|
Academic Article
|
Third-generation tyrosine kinase inhibitors and beyond.
|
Academic Article
|
Immune modulation of minimal residual disease in early chronic phase chronic myelogenous leukemia: a randomized trial of frontline high-dose imatinib mesylate with or without pegylated interferon alpha-2b and granulocyte-macrophage colony-stimulating factor.
|
Academic Article
|
Predictive factors for outcome and response in patients treated with second-generation tyrosine kinase inhibitors for chronic myeloid leukemia in chronic phase after imatinib failure.
|
Academic Article
|
Minimal cross-intolerance with nilotinib in patients with chronic myeloid leukemia in chronic or accelerated phase who are intolerant to imatinib.
|
Academic Article
|
Practical advice for determining the role of BCR-ABL mutations in guiding tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia.
|
Academic Article
|
Dynamics of chronic myeloid leukemia response to long-term targeted therapy reveal treatment effects on leukemic stem cells.
|
Academic Article
|
Pilot study of bortezomib for patients with imatinib-refractory chronic myeloid leukemia in chronic or accelerated phase.
|
Academic Article
|
Nilotinib is effective in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blastic phase.
|
Academic Article
|
Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION).
|
Academic Article
|
Analysis of outcomes in adolescents and young adults with chronic myelogenous leukemia treated with upfront tyrosine kinase inhibitor therapy.
|
Academic Article
|
Very long-term follow-up results of imatinib mesylate therapy in chronic phase chronic myeloid leukemia after failure of interferon alpha therapy.
|
Academic Article
|
Digital image analysis as a tool to assess the effects of imatinib on trabecular bone in patients with chronic myelogenous leukemia.
|
Academic Article
|
Nilotinib is associated with a reduced incidence of BCR-ABL mutations vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase.
|
Academic Article
|
Early responses predict better outcomes in patients with newly diagnosed chronic myeloid leukemia: results with four tyrosine kinase inhibitor modalities.
|
Academic Article
|
Subcutaneous omacetaxine mepesuccinate in patients with chronic-phase chronic myeloid leukemia previously treated with 2 or more tyrosine kinase inhibitors including imatinib.
|
Academic Article
|
European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.
|
Academic Article
|
Significance of deeper molecular responses in patients with chronic myeloid leukemia in early chronic phase treated with tyrosine kinase inhibitors.
|
Academic Article
|
Imatinib therapy in a patient with suspected chronic neutrophilic leukemia and FIP1L1-PDGFRA rearrangement.
|
Academic Article
|
Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: Minimum 24-month follow-up.
|
Academic Article
|
Chronic myelogenous leukemia in T cell lymphoid blastic phase achieving durable complete cytogenetic and molecular remission with imatinib mesylate (STI571; Gleevec) therapy.
|
Academic Article
|
Response of idiopathic hypereosinophilic syndrome to treatment with imatinib mesylate.
|
Academic Article
|
STI-571 in chronic myelogenous leukaemia.
|
Academic Article
|
Result of high-dose imatinib mesylate in patients with Philadelphia chromosome-positive chronic myeloid leukemia after failure of interferon-alpha.
|
Academic Article
|
The significance of myelosuppression during therapy with imatinib mesylate in patients with chronic myelogenous leukemia in chronic phase.
|
Academic Article
|
Imatinib mesylate therapy reduces bone marrow fibrosis in patients with chronic myelogenous leukemia.
|
Academic Article
|
Discontinuation of imatinib therapy after achieving a molecular response.
|
Academic Article
|
Management of patients with systemic mastocytosis: review of M. D. Anderson Cancer Center experience.
|
Academic Article
|
Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL.
|
Academic Article
|
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia.
|
Academic Article
|
Phase I/II study of subcutaneous homoharringtonine in patients with chronic myeloid leukemia who have failed prior therapy.
|
Academic Article
|
Targeting ABL and SRC kinases in chronic myeloid leukemia: experience with dasatinib.
|
Academic Article
|
Current and emerging treatment options in chronic myeloid leukemia.
|
Academic Article
|
Sensitivity of human cells bearing oncogenic mutant kit isoforms to the novel tyrosine kinase inhibitor INNO-406.
|
Academic Article
|
Suboptimal response to or failure of imatinib treatment for chronic myeloid leukemia: what is the optimal strategy?
|
Academic Article
|
Bleeding diathesis in patients with chronic myelogenous leukemia receiving dasatinib therapy.
|
Academic Article
|
Failure to achieve a complete hematologic response at the time of a major cytogenetic response with second-generation tyrosine kinase inhibitors is associated with a poor prognosis among patients with chronic myeloid leukemia in accelerated or blast phase.
|
Academic Article
|
First-line therapy for chronic myeloid leukemia: Past, present, and future.
|
Academic Article
|
Significance of increasing levels of minimal residual disease in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in complete cytogenetic response.
|
Academic Article
|
Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: two-year follow-up of a randomized phase 2 study (START-R).
|
Academic Article
|
Long-term outcome of patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations.
|
Academic Article
|
New approaches to the management of Philadelphia-chromosome-positive acute lymphocytic leukemia.
|
Academic Article
|
Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy.
|
Academic Article
|
Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results.
|
Academic Article
|
Proceedings of the Third Global Workshop on Chronic Myeloid Leukemia.
|
Academic Article
|
Early cytogenetic and molecular response during first-line treatment of chronic myeloid leukemia in chronic phase: long-term implications.
|
Academic Article
|
Role of tyrosine kinase inhibitors in the management of Philadelphia chromosome-positive acute lymphoblastic leukemia.
|
Academic Article
|
The rise and fall of gatekeeper mutations? The BCR-ABL1 T315I paradigm.
|
Academic Article
|
Molecular resistance: an early indicator for treatment change?
|
Academic Article
|
Bosutinib for the treatment of chronic myeloid leukemia in chronic phase.
|
Academic Article
|
Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study.
|
Academic Article
|
Nilotinib population pharmacokinetics and exposure-response analysis in patients with imatinib-resistant or -intolerant chronic myeloid leukemia.
|
Academic Article
|
The achievement of a 3-month complete cytogenetic response to second-generation tyrosine kinase inhibitors predicts survival in patients with chronic phase chronic myeloid leukemia after imatinib failure.
|
Academic Article
|
Detection of MRD may predict the outcome of patients with Philadelphia chromosome-positive ALL treated with tyrosine kinase inhibitors plus chemotherapy.
|
Academic Article
|
HCVAD plus imatinib or dasatinib in lymphoid blastic phase chronic myeloid leukemia.
|
Academic Article
|
Bosutinib safety and management of toxicity in leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitors.
|
Academic Article
|
Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 study.
|
Academic Article
|
Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with untreated or imatinib mesylate-resistant chronic myelogenous leukemia in blastic phase.
|
Academic Article
|
Transient benefit only from increasing the imatinib dose in CML patients who do not achieve complete cytogenetic remissions on conventional doses.
|
Academic Article
|
Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase: comparison with historic data.
|
Academic Article
|
Interleukin 11 May improve thrombocytopenia associated with imatinib mesylate therapy in chronic Myelogenous leukemia.
|
Academic Article
|
Erythropoietin is effective in improving the anemia induced by imatinib mesylate therapy in patients with chronic myeloid leukemia in chronic phase.
|
Academic Article
|
Granulocyte-colony-stimulating factor (filgrastim) may overcome imatinib-induced neutropenia in patients with chronic-phase chronic myelogenous leukemia.
|
Academic Article
|
Allogeneic stem cell transplantation for patients with chronic myeloid leukemia and acute lymphocytic leukemia after Bcr-Abl kinase mutation-related imatinib failure.
|
Academic Article
|
New targeted therapies for chronic myelogenous leukemia: opportunities to overcome imatinib resistance.
|
Academic Article
|
Plasma RNA as an alternative to cells for monitoring molecular response in patients with chronic myeloid leukemia.
|
Academic Article
|
Chromosomal abnormalities in Philadelphia chromosome negative metaphases appearing during imatinib mesylate therapy in patients with newly diagnosed chronic myeloid leukemia in chronic phase.
|
Academic Article
|
Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure.
|
Academic Article
|
Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia.
|
Academic Article
|
Characteristics and outcome of chronic myeloid leukemia patients with F317L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors.
|
Academic Article
|
Second-line therapy and beyond resistance for the treatment of patients with chronic myeloid leukemia post imatinib failure.
|
Academic Article
|
Clinical algorithms for the treatment of patients with chronic myeloid leukemia: the 2010 perspective.
|
Academic Article
|
Phase I/II multicenter study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of AZD4877 in patients with refractory acute myeloid leukemia.
|
Academic Article
|
Outcome of treatment of chronic myeloid leukemia with second-generation tyrosine kinase inhibitors after imatinib failure.
|
Academic Article
|
Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up.
|
Academic Article
|
Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION).
|
Academic Article
|
Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib.
|
Academic Article
|
Safety of bosutinib versus imatinib in the phase 3 BELA trial in newly diagnosed chronic phase chronic myeloid leukemia.
|
Academic Article
|
Current evaluation of imatinib and allogeneic transplant in the treatment of chronic myeloid leukemia.
|
Academic Article
|
Tyrosine kinase inhibitors as initial therapy for patients with chronic myeloid leukemia in accelerated phase.
|
Academic Article
|
Safety and efficacy of switching to nilotinib 400 mg twice daily for patients with chronic myeloid leukemia in chronic phase with suboptimal response or failure on front-line imatinib or nilotinib 300 mg twice daily.
|
Academic Article
|
Long-term response to imatinib is not affected by the initial dose in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: final update from the Tyrosine Kinase Inhibitor Optimization and Selectivity (TOPS) study.
|
Academic Article
|
Complete cytogenetic response, not deep molecular response, is associated with survival in chronic myeloid leukemia.
|
Academic Article
|
Final report of a phase II study of imatinib mesylate with hyper-CVAD for the front-line treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
|
Academic Article
|
A phase I study of danusertib (PHA-739358) in adult patients with accelerated or blastic phase chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant or intolerant to imatinib and/or other second generation c-ABL therapy.
|
Academic Article
|
Long-term efficacy and safety of bosutinib in patients with advanced leukemia following resistance/intolerance to imatinib and other tyrosine kinase inhibitors.
|
Academic Article
|
Targeted multigene deep sequencing of Bruton tyrosine kinase inhibitor-resistant chronic lymphocytic leukemia with disease progression and Richter transformation.
|
Academic Article
|
Targeted therapy: Generic imatinib - impact on frontline and salvage therapy for CML.
|